Etomidate Reduces Cerebral Blood Flow - PDF
Document Details
Uploaded by Deleted User
Tags
Summary
This document discusses the effects of etomidate on cerebral blood flow and intracranial pressure. It details how the drug can reduce cerebral blood flow and metabolic rate of oxygen, while maintaining or increasing cerebral perfusion pressure. The article also mentions potential neuroprotective properties of etomidate.
Full Transcript
At a dose of 0.2 to 0.3 mg/kg, etomidate reduces CBF by 34% and CMRO2 by 45% without altering MAP. CPP is maintained or increased, and there is a beneficial net increase in the cerebral oxygen supply-todemandratio. Etomidate, given in doses sufficient to produce EEG burst suppression, acutely dec...
At a dose of 0.2 to 0.3 mg/kg, etomidate reduces CBF by 34% and CMRO2 by 45% without altering MAP. CPP is maintained or increased, and there is a beneficial net increase in the cerebral oxygen supply-todemandratio. Etomidate, given in doses sufficient to produce EEG burst suppression, acutely decreases ICP by 50% in patients with already increased ICP, returning increased ICP to almost normal values. The decrease in ICP is maintained in the period immediately after intubation. To maintain the effects of etomidate on ICP, high infusion rates (60 mcg/kg/min) are necessary. Controversy remains on the neuroprotective qualities of etomidate. There is a dose-dependent increase in latency and a decreasing amplitude of the auditory evoked potentials
